Fluicell (FLUI) Q4 2024 earnings summary

Executive summary

• Achieved significant operational progress in regenerative medicine and tissue-based therapies, especially for type 1 diabetes and cardiac screening, positioning for new business opportunities and market strength.

• Strategic focus shifted towards tissue-based products, with major investments in Nexocyte platform and expansion of patent portfolio in EU and US.

• Accelerated development in type 1 diabetes therapies, with successful in vivo studies and new partnerships.

Financial highlights

• Q4 2024 net revenue increased 144% to 515 KSEK (211 KSEK), mainly from higher consumables sales.

• Q4 total operating income rose 835% to 4,991 KSEK (534 KSEK), driven by new accounting for R&D costs.

• Q4 EBITDA improved to -1,735 KSEK (-7,997 KSEK); operating result to -1,830 KSEK (-8,124 KSEK).

• Full-year 2024 net revenue fell 44% to 1,859 KSEK (3,338 KSEK) due to strategic shift; total income up 128% to 10,566 KSEK (4,631 KSEK).

• Full-year operating result improved to -15,842 KSEK (-26,879 KSEK); EPS -0.03 SEK (-0.98 SEK).

• Year-end cash position at 15,924 KSEK (2,763 KSEK), supported by capital raises.

Outlook and guidance

• Continued focus on commercializing tissue-based therapies and models, especially for type 1 diabetes and cardiac safety.

• Ongoing investments in regenerative medicine expected to require further financing; board confident in securing necessary funds.

• Strategic shift and cost savings expected to further improve results in 2025.